Department of Pediatrics I, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria.
Expert Rev Mol Diagn. 2011 Jul;11(6):561-5. doi: 10.1586/erm.11.39.
The therapeutic management of patients with lupus nephritis (LN) remains a major challenge. The availability of biomarkers that accurately predict renal flares, response to immunosuppressive treatment and risk of progression to end-stage renal disease would allow the more effective use of currently available immunosuppression, with less toxicity. The molecular analysis of renal biopsy samples provides direct insights into pathologic processes in LN, and constitutes a valuable approach to discover biomarkers that may be used to improve the outcome of LN patients. Reich et al. recently described a method for simultaneously detecting multiple mRNA transcripts in archived formalin-fixed renal biopsy samples. The authors identify three transcripts (EGF, MMP7 and COL1A1) that relate to pathological indices of kidney injury and function.
狼疮肾炎（LN）患者的治疗管理仍然是一个主要挑战。如果有生物标志物能够准确预测肾复发、免疫抑制治疗的反应以及进展为终末期肾病的风险，将有助于更有效地利用现有的免疫抑制剂，同时减少毒性。对肾活检样本的分子分析可直接了解 LN 中的病理过程，是发现可能改善 LN 患者预后的生物标志物的一种有价值的方法。Reich 等人最近描述了一种在存档的福尔马林固定肾活检样本中同时检测多种 mRNA 转录本的方法。作者确定了与肾脏损伤和功能的病理指标相关的三个转录本（EGF、MMP7 和 COL1A1）。
